Non-Hodgkin Lymphoma

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

By

A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

Relapsed/Refractory DLBCL Added to Approved CAR-T Cell Therapy Indications

By

FDA approval was based on results of the single-arm phase 2 JULIET clinical trial.

Durable Tumor Response Seen in Some Lymphomas With Tazemetostat

Durable Tumor Response Seen in Some Lymphomas With Tazemetostat

By

Tazemetostat demonstrated preclinical activity against EZH2­-mutant non-Hodgkin lymphomas.

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

By

The ability to make early adjustments to treatment has the potential to improve survival.

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

By

In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides

By

The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

Palonosetron Prevents Delayed Nausea and Vomiting After CHOP in Non-Hodgkin Lymphoma

By

Palonosetron effectively prevents and manages delayed CINV in patients with non-Hodgkin lymphoma.

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape

[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma

By

The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.

NHL: Adolescent BMI, Height Linked With Subtype Risks

NHL: Adolescent BMI, Height Linked With Subtype Risks

By

Higher body weight and increased height during adolescence increase the risk for developing certain subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.

No Risk of Second Primary Malignancies in Patients With NHL Receiving Rituximab

No Risk of Second Primary Malignancies in Patients With NHL Receiving Rituximab

By

Survivors of non-Hodgkin lymphoma (NHL) exposed to rituximab do not have an increased risk for developing second primary malignancies.

Timing Matters for Pegfilgrastim Administration

Timing Matters for Pegfilgrastim Administration

By

The incidence of febrile neutropenia was significantly higher among patients who received pegfilgrastim prophylaxis on the same day.

Breakthrough Advance Announced in International Blood Cancer Drug Trial

By

Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.

Follow-up PET/CT more than 95% sensitive for non-Hodgkin lymphoma

By

BALTIMORE, MD—For more aggressive cases of non-Hodgkin lymphoma (NHL), posttreatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment. This was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 Annual Meeting.

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.

Changes in cancer epigenome implicated in chemotherapy resistance and lymphoma relapse

By

New research indicate that malfunctioning genes are only partly to blame for why treatment that was effective ultimately fails in many patients with the most common form of non-Hodgkin lymphoma.

Infertile men at a greater risk for all cancers

Infertile men at a greater risk for all cancers

Compared with the vasectomy and control groups, infertile men had a higher risk of testis cancer, non-Hodgkin lymphoma, and all cancers.

Intense exercise may decrease non-Hodgkin lymphoma risk

Intense exercise may decrease non-Hodgkin lymphoma risk

Intense physical activity throughout life is linked to a 30 percent reduction in risk.

Lifetime vigorous physical activity may be beneficial in lowering risk for non-Hodgkin lymphoma

Lifetime vigorous physical activity may be beneficial in lowering risk for non-Hodgkin lymphoma

Level of physical activity over a lifetime can impact risk for non-Hodgkin lymphoma (NHL).

Low vitamin D linked to worse prognosis in a type of non-Hodgkin lymphoma

Low vitamin D linked to worse prognosis in a type of non-Hodgkin lymphoma

By

A lower vitamin D levels prior to treatment for follicular lymphoma has been linked to earlier relapse and increased mortality, according to a new study.

Targeting survival protein may counter drug-resistance in non-Hodgkin lymphomas

By

Targeting a specific cell survival protein could be key to treating some lymphomas, including those with genetic defects that make them resistant to standard therapies.

Response to new drug in patients with lymphomas and advanced solid tumors

Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.

New drug for non-Hodgkin lymphoma and chronic leukemia succeeds in phase I

By

A new chemotherapy drug being investigated for its potency against two types of cancer was found to be effective in about one-third of the participants in a phase I study.

Inhibitor idelalisib active in non-Hodgkin lymphoma

Inhibitor idelalisib active in non-Hodgkin lymphoma

The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Genetic driver of Waldenström macroglobulinemia identified

By

In nearly one-third of patients with Waldenström macroglobulinemia, the disease is switched on by a specific genetic mutation. A new drug that blocks the defective gene can arrest the disease in animal models, according to research reported at the 2013 ASH Annual Meeting, in New Orleans.

Drug-antibody pair has promising activity in non-Hodgkin lymphoma

By

A toxin linked to a targeted monoclonal antibody has shown compelling antitumor activity in patients with non-Hodgkin lymphomas (NHLs) who were no longer responding to treatment, according to a new report.

Longer remissions with early stem cell transplants for non-Hodgkin lymphoma

By

Performing early stem cell transplants in patients with aggressive non-Hodgkin lymphoma does not improve overall survival in high-risk patients, according to a new study. However, early transplantation appears to be beneficial among the small group of patients who are at the very highest risk.

PET/CT better than bone marrow biopsy for lymphoma diagnosis

By

Assessing bone marrow involvement in persons with a new diagnosis of diffuse large B-cell lymphoma (DLBCL) is better accomplished with 18F-FDG positron emission tomography/computed tomography (PET/CT).

Antiretroviral therapy has not improved survival of HIV-associated lymphoma

By

Survival rates were stable for patients with HIV-associated lymphoma during the antiretroviral therapy (ART) era in the United States, according to a new study.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs